The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>In vitro</i> and <i>In vivo</i>
Clinical cancer research